Story
Technology
Pipeline
People
Join us
People
People
Join us
News
Contact us
Pipeline
We take aim at the world’s most intractable diseases. Our portfolio spans both novel and known (but traditionally undruggable) targets.
Indication
rModality
Target
Discovery
Pre-clinical
Clinical
IL-2
Cancer & Metabolic
MYC
Cancer & Immunity
Inflamm. & Immunity
SM
SM
SM
SM
SM
ASO
SM
SM
FLCN
Cancer & Immunity
Inflamm. & Immunity
IL-1β
SM
SM
FLCN
RAS
FLCN
ALS
FTD/AD
Cancer
ALS
IL-1α
IL-1RA
PTPN2
Inflamm. & Immunity
SM = small molecule
rModality = RNA-targeted modality